Key facts
- Notable investors include Wuxi Capital, Chengmei Ventures, Render Help, Shanghai Angel Group.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Toursun Synbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Toursun Synbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Toursun Synbio
Developer of AI-driven protein design platforms aims to accelerate synthetic biology innovation. The company leverages multimodal and vertical large models, generative AI, and integrated wet-lab validation to serve biopharma and synthetic biology enterprises, enabling faster protein engineering, enzyme optimization, and high-value product development.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Employees
- 14
- Website
- toursynbio.com/
- Ownership
- Privately Held (backing)
Toursun Synbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Toursun Synbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Toursun Synbio in its N-PORT filings yet. We sweep new filings monthly.